Navigation Links
Active Ingredient in Viagra Shrunk Disfiguring Growths in Kids
Date:1/25/2012

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, Jan. 25 (HealthDay News) -- A new preliminary report suggests that the active ingredient in Viagra, sildenafil, could reduce the size of large growths that can disfigure the bodies of children.

The findings could point to yet another use for the medicine, which was first developed as a heart medication until researchers noticed that it helped impotent men have erections. This time, researchers stumbled upon an alternate use while using a Viagra-like drug to treat a rare condition that causes high blood pressure in the arteries that lead to the lungs.

There are caveats: The treatment is very expensive, the research is only in its early stages, and the medication may not be a cure. Still, the research raises the prospect that "we could treat some of these little kids who have little or no hope," said report co-author Dr. Alfred Lane, a professor of dermatology and pediatrics at Stanford University School of Medicine.

The growths in question are known as severe lymphatic malformations. They appear in children, including babies, and create disfiguring growths of fluid and vessels.

The growths can be as big as a volleyball or a basketball, Lane said. They seem to appear when the lymphatic system, a component of the body's immune system, becomes clogged, although the exact cause isn't clear, he said.

In some cases, the growths can be dangerous, such as when they pose a risk of blocking an airway pressuring a nearby organ.

Surgery to remove the growth is one option, although it may not be possible, he said. For some children, "there's not a whole lot you can do about it."

That's where sildenafil may help.

Researchers used a form of the medication called Revatio to treat a baby girl who suffered from pulmonary hypertension, the condition that causes high blood pressure in certain arteries. The investigators found that the medication had another effect: it reduced the size of a lymphatic growth.

The child, who was severely ill, died. But researchers were curious about the effects of the drug, and they tried it on two other children. Their growths shrunk and became softer after 12 weeks.

The parents of the children decided to continue giving the drug to their kids; it's not clear how they're doing now, but Lane will see one of the patients soon.

The drug may not eliminate a growth, "but if it can reduce it to the size that they can remove it, that would be good," Lane said.

Revatio costs $800 to $1,000 a month, Lane said, although the Pfizer drug company is donating the drug for research purposes. While the dose is low, potential side effects include dizziness, eye problems, nosebleeds and nausea, Lane said.

Researchers don't know how the drug works to reduce the size of the growths, Lane noted, although one possibility is that it makes it easier for the lymph system to drain fluid.

A new study of the treatment is underway.

Dr. Richard Smith, a pediatric otolaryngologist who's familiar with the report, said it offers an "exciting and serendipitous finding." But it must still be validated to prove that it truly holds promise, said Smith, vice chair of the University of Iowa's department of otolaryngology -- head and neck surgery.

The report appears in the Jan. 26 issue of the New England Journal of Medicine.

More information

Children's Hospital Boston has details about lymphatic malformations.

SOURCES: Alfred Lane, M.D., professor, dermatology and pediatrics, Stanford University School of Medicine, Palo Alto, Calif.; Richard Smith, M.D., pediatric otolaryngologist, and vice chair, department of otolaryngology -- head and neck surgery, University of Iowa, Iowa City; Jan. 26, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. The concept of overactive bladder serves better commercial rather than patient interests
2. Safety-First Playgrounds Linked to Bored, Inactive Kids: Study
3. Novel experimental agent is highly active in CLL patients, interim study shows
4. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
5. Active Surveillance May Benefit Men With Low-Risk Prostate Cancer
6. Moffitt Cancer Center researchers find MK1775 active against sarcomas
7. More years to life and life to years through increased motivation for an active life
8. Lower income dads active in their kids health
9. Practical play: Interactive video games appear valuable for ICU patients
10. Big Tobacco knew radioactive particles in cigarettes posed cancer risk but kept quiet
11. Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Active Ingredient in Viagra Shrunk Disfiguring Growths in Kids
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: